Found: 1020
Select item for more details and to access through your institution.
Effects of sodium-glucose co-transporter 2 inhibitors on ultrafiltration in patients with peritoneal dialysis: a protocol for a randomized, double-blind, placebo-controlled, crossover trial (EMPOWERED).
- Published in:
- Clinical & Experimental Nephrology, 2024, v. 28, n. 7, p. 629, doi. 10.1007/s10157-024-02467-w
- By:
- Publication type:
- Article
Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA–KIDNEY.
- Published in:
- Clinical & Experimental Nephrology, 2024, v. 28, n. 6, p. 588, doi. 10.1007/s10157-024-02489-4
- By:
- Publication type:
- Article
Investigation of the effect of Acai berry on the pharmacokinetics of Atorvastatin, Alogliptin and Empagliflozin: a herb–drug interaction study.
- Published in:
- Journal of Pharmacy & Pharmacology, 2022, v. 74, n. 8, p. 1125, doi. 10.1093/jpp/rgac022
- By:
- Publication type:
- Article
تأثیر شش هفته تمرین استقامتی و دریافت امپاگلیفلوزین بر شاخصهای ساختاری و عملکردی قلب رت های نر دیابتی شده با STZ.
- Published in:
- Journal of Ilam University of Medical Sciences, 2022, v. 30, n. 3, p. 1
- By:
- Publication type:
- Article
«SGLT2 INHIBITORS: RATIONALE FOR THE USE IN HEART FAILURE», RESOLUTION ON THE RESULTS OF THE PANEL OF EXPERTS WITH INTERNATIONAL PARTICIPATION, ALMATY.
- Published in:
- Interdisciplinary Approaches to Medicine, 2022, v. 3, n. 2, p. 38, doi. 10.26577/IAM.2022.v3.i2.08
- By:
- Publication type:
- Article
SGLT-2 INHIBITORS AS POTENTIAL ANTICONVULSANTS: EMPAGLIFLOZIN, BUT NOT DAPAGLIFLOZIN, RENDERS A PRONOUNCED EFFECT AND POTENTIATES THE SODIUM VALPROATE ACTIVITY IN PENTYLENETETRAZOLE-INDUCED SEIZURES.
- Published in:
- ScienceRise: Pharmaceutical Science, 2022, v. 39, n. 5, p. 83, doi. 10.15587/2519-4852.2022.266065
- By:
- Publication type:
- Article
Acute Occlusion of a "Protected" Left Main Coronary Artery Manifesting as an Acute Coronary Syndrome with Heart Failure: How much Protected it is?
- Published in:
- Indian Journal of Clinical Cardiology, 2023, v. 4, n. 4, p. 295, doi. 10.1177/26324636231212023
- By:
- Publication type:
- Article
Empagliflozin and Dapagliflozin Reduce ROS Generation and Restore NO Bioavailability in Tumor Necrosis Factor α-Stimulated Human Coronary Arterial Endothelial Cells.
- Published in:
- Cellular Physiology & Biochemistry (Cell Physiol Biochem Press GmbH & Co. KG), 2019, v. 53, n. 5, p. 865, doi. 10.33594/000000178
- By:
- Publication type:
- Article
Oral semaglutide in kidney transplant recipients with metabolic syndrome: three Japanese cases.
- Published in:
- Renal Replacement Therapy, 2023, v. 9, n. 1, p. 1, doi. 10.1186/s41100-023-00492-1
- By:
- Publication type:
- Article
Empagliflozin.
- Published in:
- SA Pharmaceutical Journal Incorporating Pharmacy Management, 2019, v. 86, n. 2, p. 45
- By:
- Publication type:
- Article
SGLT2 inhibitors.
- Published in:
- SA Pharmaceutical Journal Incorporating Pharmacy Management, 2018, v. 85, n. 1, p. 72
- By:
- Publication type:
- Article
Effect of sodium-glucose transporter 2 inhibitors on bone.
- Published in:
- Journal of Parathyroid Disease, 2023, v. 11, n. 1, p. 1, doi. 10.34172/jpd.2023.11225
- By:
- Publication type:
- Article
SGLT2 Inhibitors: A Noval Therapuetic Agent in the Treatment of Diabetic Kidney Disease.
- Published in:
- Journal of Drug Delivery & Therapeutics, 2020, v. 10, n. 6, p. 203, doi. 10.22270/jddt.v10i6.4532
- By:
- Publication type:
- Article
In-Vitro Antioxidant Activity and Free Radical Scavenging Potential of Phlorizin Derived Sodium Glucose Cotransporter 2 Inhibitor.
- Published in:
- Journal of Drug Delivery & Therapeutics, 2019, v. 9, n. 4, p. 257, doi. 10.22270/jddt.v9i4.3038
- By:
- Publication type:
- Article
Empagliflozin Effects in Patients with ST-Elevation Myocardial Infarction Undergoing Primary PCI: The EMI-STEMI Randomized Clinical Trial.
- Published in:
- American Journal of Cardiovascular Drugs, 2024, v. 24, n. 5, p. 673, doi. 10.1007/s40256-024-00662-4
- By:
- Publication type:
- Article
Comparative Genitourinary Safety of In-class Sodium-Glucose Cotransporter-2 Inhibitors among Patients with Heart Failure with Preserved Ejection Fraction: A Cohort Study.
- Published in:
- American Journal of Cardiovascular Drugs, 2024, v. 24, n. 3, p. 455, doi. 10.1007/s40256-024-00648-2
- By:
- Publication type:
- Article
Practical Guidance for the Use of SGLT2 Inhibitors in Heart Failure.
- Published in:
- American Journal of Cardiovascular Drugs, 2023, v. 23, n. 6, p. 609, doi. 10.1007/s40256-023-00601-9
- By:
- Publication type:
- Article
Effect of Dapagliflozin Versus Empagliflozin on Cardiovascular Death in Patients with Heart Failure Across the Spectrum of Ejection Fraction: Cost per Outcome Analysis.
- Published in:
- American Journal of Cardiovascular Drugs, 2023, v. 23, n. 3, p. 323, doi. 10.1007/s40256-023-00578-5
- By:
- Publication type:
- Article
Cost-Effectiveness of Adding Empagliflozin to Standard Treatment for Heart Failure with Preserved Ejection Fraction Patients in China.
- Published in:
- American Journal of Cardiovascular Drugs, 2023, v. 23, n. 1, p. 47, doi. 10.1007/s40256-022-00550-9
- By:
- Publication type:
- Article
Cost-Utility Analysis of Combination Empagliflozin and Standard Treatment Versus Standard Treatment Alone in Thai Heart Failure Patients with Reduced or Preserved Ejection Fraction.
- Published in:
- American Journal of Cardiovascular Drugs, 2022, v. 22, n. 5, p. 577, doi. 10.1007/s40256-022-00542-9
- By:
- Publication type:
- Article
Empagliflozin attenuates doxorubicin-induced cardiotoxicity.
- Published in:
- Toxicology Research, 2023, v. 12, n. 5, p. 998, doi. 10.1093/toxres/tfad071
- By:
- Publication type:
- Article
Empagliflozin attenuates doxorubicin-induced cardiotoxicity by activating AMPK/SIRT-1/PGC-1α-mediated mitochondrial biogenesis.
- Published in:
- Toxicology Research, 2023, v. 12, n. 2, p. 216, doi. 10.1093/toxres/tfad007
- By:
- Publication type:
- Article
EMMY: The continued expansion of clinical applications of SGLT2 inhibitors.
- Published in:
- Global Cardiology Science & Practice, 2023, v. 2023, n. 1, p. 1, doi. 10.21542/gcsp.2023.5
- By:
- Publication type:
- Article
EMPEROR-Preserved: SGLT2 inhibitors breakthrough in the management of heart failure with preserved ejection fraction.
- Published in:
- Global Cardiology Science & Practice, 2021, v. 2021, n. 3, p. 1, doi. 10.21542/gcsp.2021.17
- By:
- Publication type:
- Article
Empagliflozin ameliorated neutropenia in a girl with glycogen storage disease Ib.
- Published in:
- 2021
- By:
- Publication type:
- Case Study
Effect of SGLT-2 inhibitor, empagliflozin, on blood pressure reduction in Chinese elderly hypertension patients with type 2 diabetes and its possible mechanisms.
- Published in:
- Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-07395-x
- By:
- Publication type:
- Article
Empagliflozin maintains capillarization and improves cardiac function in a murine model of left ventricular pressure overload.
- Published in:
- Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-97787-2
- By:
- Publication type:
- Article
Early combination therapy of empagliflozin and linagliptin exerts beneficial effects on pancreatic β cells in diabetic db/db mice.
- Published in:
- Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-94896-w
- By:
- Publication type:
- Article
Decoding empagliflozin's molecular mechanism of action in heart failure with preserved ejection fraction using artificial intelligence.
- Published in:
- Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-91546-z
- By:
- Publication type:
- Article
Cardioprotective effects of empagliflozin after ischemia and reperfusion in rats.
- Published in:
- Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-89149-9
- By:
- Publication type:
- Article
Long‐term follow up of a single case of metabolic surgery in an elderly Japanese patient with severe obesity.
- Published in:
- 2024
- By:
- Publication type:
- Letter to the Editor
Case report: A case of Rabson-Mendenhall syndrome: long-term follow-up and therapeutic management with empagliflozin.
- Published in:
- Frontiers in Genetics, 2024, p. 1, doi. 10.3389/fgene.2024.1414451
- By:
- Publication type:
- Article
Empagliflozin Contributes to Polyuria via Regulation of Sodium Transporters and Water Channels in Diabetic Rat Kidneys.
- Published in:
- Frontiers in Physiology, 2019, p. N.PAG, doi. 10.3389/fphys.2019.00271
- By:
- Publication type:
- Article
The impact of SGLT2 inhibitors on αKlotho in renal MDCK and HK-2 cells.
- Published in:
- Frontiers in Endocrinology, 2023, v. 14, p. 01, doi. 10.3389/fendo.2023.1069715
- By:
- Publication type:
- Article
Effects of empagliflozin on the expression of kisspeptin gene and reproductive system function in streptozotocin-induced diabetic male rats.
- Published in:
- Frontiers in Endocrinology, 2022, v. 13, p. 1, doi. 10.3389/fendo.2022.1059942
- By:
- Publication type:
- Article
Empagliflozin reduces diffuse myocardial fibrosis by extracellular volume mapping: A meta-analysis of clinical studies.
- Published in:
- Frontiers in Endocrinology, 2022, v. 13, p. 1, doi. 10.3389/fendo.2022.917761
- By:
- Publication type:
- Article
Empagliflozin Attenuates Obesity-Related Kidney Dysfunction and NLRP3 Inflammasome Activity Through the HO-1–Adiponectin Axis.
- Published in:
- Frontiers in Endocrinology, 2022, v. 13, p. 1, doi. 10.3389/fendo.2022.907984
- By:
- Publication type:
- Article
Comparative Cardiovascular Outcomes of SGLT2 Inhibitors in Type 2 Diabetes Mellitus: A Network Meta-Analysis of Randomized Controlled Trials.
- Published in:
- Frontiers in Endocrinology, 2022, v. 13, p. 1, doi. 10.3389/fendo.2022.802992
- By:
- Publication type:
- Article
Efficacy and Safety of Empagliflozin on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
- Published in:
- Frontiers in Endocrinology, 2022, v. 13, p. 1, doi. 10.3389/fendo.2022.836455
- By:
- Publication type:
- Article
Use of Oral Empagliflozin to Obtain Optimal Blood Sugar Levels for Conducting <sup>18</sup> F-FDG PET-CT in Patients with Hyperglycemia—A Pilot Study.
- Published in:
- World Journal of Nuclear Medicine, 2023, v. 22, n. 3, p. 191, doi. 10.1055/s-0043-1771283
- By:
- Publication type:
- Article
The Effect of Additional Treatment with Empagliflozin or Semaglutide on Endothelial Function and Arterial Stiffness in Subjects with Type 1 Diabetes Mellitus—ENDIS Study.
- Published in:
- Pharmaceutics, 2023, v. 15, n. 7, p. 1945, doi. 10.3390/pharmaceutics15071945
- By:
- Publication type:
- Article
A Model-Informed Drug Development (MIDD) Approach for a Low Dose of Empagliflozin in Patients with Type 1 Diabetes.
- Published in:
- Pharmaceutics, 2021, v. 13, n. 4, p. 485, doi. 10.3390/pharmaceutics13040485
- By:
- Publication type:
- Article
A Population Pharmacokinetic Study to Compare a Novel Empagliflozin L-Proline Formulation with Its Conventional Formulation in Healthy Subjects.
- Published in:
- Pharmaceuticals (14248247), 2024, v. 17, n. 4, p. 522, doi. 10.3390/ph17040522
- By:
- Publication type:
- Article
Acute Kidney Injury and Electrolyte Imbalances Caused by Dapagliflozin Short-Term Use.
- Published in:
- Pharmaceuticals (14248247), 2024, v. 17, n. 4, p. 420, doi. 10.3390/ph17040420
- By:
- Publication type:
- Article
Empagliflozin Protects against Haloperidol Experimentally-Induced Ovarian Toxicity.
- Published in:
- Pharmaceuticals (14248247), 2023, v. 16, n. 2, p. 168, doi. 10.3390/ph16020168
- By:
- Publication type:
- Article
The Impact of an SGLT2 Inhibitor versus Ursodeoxycholic Acid on Liver Steatosis in Diabetic Patients.
- Published in:
- Pharmaceuticals (14248247), 2022, v. 15, n. 12, p. 1516, doi. 10.3390/ph15121516
- By:
- Publication type:
- Article
Pharmacokinetics and Bioequivalence of Two Empagliflozin, with Evaluation in Healthy Jordanian Subjects under Fasting and Fed Conditions.
- Published in:
- Pharmaceuticals (14248247), 2022, v. 15, n. 2, p. 193, doi. 10.3390/ph15020193
- By:
- Publication type:
- Article
Empagliflozin—A New Chance for Patients with Chronic Heart Failure.
- Published in:
- Pharmaceuticals (14248247), 2022, v. 15, n. 1, p. 47, doi. 10.3390/ph15010047
- By:
- Publication type:
- Article
Effects of NPY-2 Receptor Antagonists, Semaglutide, PYY 3-36 , and Empagliflozin on Early MASLD in Diet-Induced Obese Rats.
- Published in:
- Nutrients, 2024, v. 16, n. 6, p. 904, doi. 10.3390/nu16060904
- By:
- Publication type:
- Article
Identification of Key Immune-Related Genes in the Treatment of Heart Failure After Myocardial Infarction with Empagliflozin Based on RNA-Seq.
- Published in:
- Journal of Inflammation Research, 2023, v. 16, p. 4679, doi. 10.2147/JIR.S428747
- By:
- Publication type:
- Article